View in EDS HTML Full Text PDF Full Text

18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.

Saved in:
Bibliographic Details
Title: 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Authors: Machado Medeiros, Tássia1 (AUTHOR), Altmayer, Stephan1,2 (AUTHOR), Watte, Guilherme1 (AUTHOR), Zanon, Matheus2,3 (AUTHOR), Basso Dias, Adriano2 (AUTHOR), Henz Concatto, Natália4 (AUTHOR), Hoefel Paes, Julia1 (AUTHOR), Mattiello, Rita1 (AUTHOR), de Souza Santos, Francisco1 (AUTHOR), Mohammed, Tan-Lucien5 (AUTHOR), Verma, Nupur5 (AUTHOR), Hochhegger, Bruno1,2,3 (AUTHOR) brunoho@ufcspa.edu.br
Source: European Radiology. Jul2020, Vol. 30 Issue 7, p3641-3649. 9p. 1 Diagram, 1 Chart, 3 Graphs.
Subjects: Non-small-cell lung carcinoma, Fluorodeoxyglucose F18, Positron emission tomography computed tomography, Magnetic resonance imaging, Meta-analysis, Lung cancer, Research, Research methodology, Lung tumors, Evaluation research, Medical cooperation, Diagnostic imaging, Tumor classification, Comparative studies, Radiopharmaceuticals, Deoxy sugars
Abstract: Objectives: To evaluate the diagnostic test accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), whole-body magnetic resonance imaging (WB-MRI), and whole-body diffusion-weighted imaging (WB-DWI) for the detection of metastases in patients with non-small cell lung cancer (NSCLC).Methods: MEDLINE, Embase, and Cochrane Library databases were searched up to June 2019. Studies were selected if they reported data that could be used to construct contingency tables to compare 18F-FDG PET/CT, WB-MRI, and WB-DWI. Two authors independently extracted data on study characteristics and assessed methodological quality using the Quality Assessment of Diagnostic Accuracy Studies. Forest plots were generated for sensitivity and specificity of 18F-FDG PET/CT, WB-MRI, and whole-body diffusion-weighted imaging (WB-DWI). Summary receiver operating characteristic plots were created.Results: The 4 studies meeting inclusion criteria had a total of 564 patients and 559 lesions, 233 of which were metastases. In studies of 18F-FDG PET/CT, the pooled estimates of sensitivity and specificity were 0.83 (95% confidence interval [CI], 0.54-0.95) and 0.93 (95% CI, 0.87-0.96), respectively. For WB-MRI, pooled sensitivity was 0.92 (95% CI, 0.18-1.00) and pooled specificity was 0.93 (95% CI, 0.85-0.95). Pooled sensitivity and specificity for WB-DWI were 0.78 (95% CI, 0.46-0.93) and 0.91 (95% CI, 0.79-0.96), respectively. There was no statistical difference between the diagnostic odds ratio of WB-MRI and WB-DWI compared with that of PET/CT (p = 0.186 for WB-DWI; p = 0.638 for WB-MRI).Conclusion: WB-MRI and DWI are radiation-free alternatives with comparable diagnostic performance to 18F-FDG PET/CT for M staging of NSCLC.Key Points: • Whole-body MRI with or without diffusion-weighted imaging has a high accuracy for the diagnostic evaluation of metastases in patients with non-small cell lung cancer. • Whole-body MRI may be used as a non-invasive and radiation-free alternative to positron emission tomography with CT with similar diagnostic performance. [ABSTRACT FROM AUTHOR]
Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first